CN110430874A - N-(2-氨乙基)-n-(4-苄氧基)-3-甲氧基苄基)噻吩-2-甲酰胺盐酸盐的医药用途 - Google Patents

N-(2-氨乙基)-n-(4-苄氧基)-3-甲氧基苄基)噻吩-2-甲酰胺盐酸盐的医药用途 Download PDF

Info

Publication number
CN110430874A
CN110430874A CN201780085171.0A CN201780085171A CN110430874A CN 110430874 A CN110430874 A CN 110430874A CN 201780085171 A CN201780085171 A CN 201780085171A CN 110430874 A CN110430874 A CN 110430874A
Authority
CN
China
Prior art keywords
administration
benzyloxy
aminoethyl
thiophene
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780085171.0A
Other languages
English (en)
Inventor
徐迅迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Xiangya Hospital of Central South University
Original Assignee
Second Xiangya Hospital of Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Xiangya Hospital of Central South University filed Critical Second Xiangya Hospital of Central South University
Publication of CN110430874A publication Critical patent/CN110430874A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Abstract

本发明涉及N‑(2‑氨乙基)‑N‑(4‑苄氧基)‑3‑甲氧基苄基)噻吩‑2‑甲酰胺盐酸盐用于治疗肝癌的用途。本发明的N‑(2‑氨乙基)‑N‑(4‑苄氧基)‑3‑甲氧基苄基)噻吩‑2‑甲酰胺盐酸盐能够有效抑制肝癌细胞的生长，对肝癌起到治疗作用。

Description

PCT国内申请，说明书已公开。

Claims (8)

  1. PCT国内申请，权利要求书已公开。
CN201780085171.0A 2017-03-08 2017-03-08 N-(2-氨乙基)-n-(4-苄氧基)-3-甲氧基苄基)噻吩-2-甲酰胺盐酸盐的医药用途 Pending CN110430874A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/075943 WO2018161271A1 (zh) 2017-03-08 2017-03-08 N-(2-氨乙基)-n-(4-苄氧基)-3-甲氧基苄基)噻吩-2-甲酰胺盐酸盐的医药用途

Publications (1)

Publication Number Publication Date
CN110430874A true CN110430874A (zh) 2019-11-08

Family

ID=63447100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780085171.0A Pending CN110430874A (zh) 2017-03-08 2017-03-08 N-(2-氨乙基)-n-(4-苄氧基)-3-甲氧基苄基)噻吩-2-甲酰胺盐酸盐的医药用途

Country Status (4)

Country Link
US (1) US10736873B2 (zh)
EP (1) EP3593798A4 (zh)
CN (1) CN110430874A (zh)
WO (1) WO2018161271A1 (zh)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515950A (ja) 2004-10-13 2008-05-15 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用の冷メントール受容体−１（ｃｍｒ−１）アンタゴニストとしての４−置換ベンジルオキシ−フェニルメチルアミド誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. CAMILA ALMEIDA等.: "Pharmacological Blockade of the Cold Receptor TRPM8 Attenuates Autonomic and Behavioral Cold Defenses and Decreases Deep Body Temperature", 《THE JOURNAL OF NEUROSCIENCE》 *
刘杰锋: "《中国优秀硕士学位论文 全文数据库医药卫生科技辑》", 15 February 2012 *

Also Published As

Publication number Publication date
WO2018161271A1 (zh) 2018-09-13
US20200000769A1 (en) 2020-01-02
US10736873B2 (en) 2020-08-11
EP3593798A1 (en) 2020-01-15
EP3593798A4 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
US10624869B2 (en) Methods for the treatment of recurrent glioblastoma (RGBM)
CN102475710B (zh) 薯蓣皂苷元及其衍生物在制备肿瘤化疗增敏药物中的应用
CN105476996B (zh) 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途
WO2021218965A1 (zh) 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
CN103191095B (zh) 一种stat3信号通路小分子抑制剂及其在制备抗肿瘤药物中的应用
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
TW202114682A (zh) Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
CN110430874A (zh) N-(2-氨乙基)-n-(4-苄氧基)-3-甲氧基苄基)噻吩-2-甲酰胺盐酸盐的医药用途
CN107362163A (zh) 一种治疗肠癌的药物制剂
CN113329745A (zh) 一种有效抗恶性肿瘤的药物组合物及其应用
WO2020057632A1 (zh) 硒氰化合物及其用途
CN105663147B (zh) 4-羟基水杨酰苯胺在制备抗肿瘤药物中的应用
CN102319260A (zh) 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用
CN109966275B (zh) 醌式查尔酮化合物在制备抗肿瘤药物中的应用
CN108567768B (zh) 对-[(二丙氨基)磺酰基]苯甲酸的医药用途
CN106540255A (zh) 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
CN112603920A (zh) 一种中药川楝素在制备防治神经系统胶质瘤产品中的应用
CN111558045A (zh) 一种治疗肺癌的药物组合物
CN111728960B (zh) 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用
CN111939165B (zh) 非天然人参皂苷3β-O-Glc-DM在制备预防或治疗胶质母细胞瘤药物中的应用
WO2021196335A1 (zh) Pyr3的用途
CN109464441B (zh) 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用
CN103417620A (zh) 溪黄草提取物作为stat3信号特异性抑制剂在制备抗肿瘤药物中的应用
CN108042545B (zh) 盐酸氮卓斯汀在制备抑制结肠癌肿瘤生长药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191108

RJ01 Rejection of invention patent application after publication